Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)

NCT07804966 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT07804966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07804966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Trial of Sacituzumab Tirumotecan (Sac-TMT) as Second-line Treatment for Advanced/Metastatic Vaginal and Vulvar Squamous Cell Carcinoma - ARCANA Trial (LACOG 1724)
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2032
Enrollment
48 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

vaginal squamous cell carcinoma, vulvar squamous cell carcinoma